Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging

NCT06632912 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Papillomavirus (HPV) Infection
HPV (Human Papillomavirus)-Associated Carcinoma

Interventions

BIOLOGICAL: 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
BIOLOGICAL: 3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

Sponsor

National Vaccine and Serum Institute, China

Collaborators

[object Object]